Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Medivation Inc. and Astellas Pharma Inc. announced that new data for enzalutamide , an oral androgen receptor inhibitor, were presented today at the 2012 European Society of Medical Oncology ...

Today, Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with ...

“Over a year has passed since the petition to exercise march-in rights for Xtandi was first submitted to HHS," lawmakers wrote to the agency's leader.

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%After a median follow-up of 61.4 months ...